Stephen C. Rubin - Concepedia

Author

Stephen C. Rubin

Memorial Sloan Kettering Cancer Center ORCID

Also Known As

Monk, Bradley J, S C Rubin, S CRUBIN, S RUBIN, S Rubin, S. C. Rubin, S. Ru-bin, S. Rubin, S.C. RUBIN, S.C. Rubin

406

Publications

21.5K

Citations

H-Index

161

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center University of Pennsylvania Fox Chase Cancer Center Gynecologic Oncology Group Hospital of the University of Pennsylvania

About

Stephen C. Rubin is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, obstetrics, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	54	119	10.6K
2	Health Sciences	10	10	855
3	Nursing	2	2	110
4	Education	1	1	35
5	Engineering	1	1	23

Stephen C. Rubin

185

Publications

20K

Citations

H-Index

Page 1

	Year	Citations
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer Lin Zhang, José R. Conejo-García, Dionyssios Katsaros, New England Journal of Medicine	2003	3.4K
Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. E.Y. Woo, Christina Chu, Theresa J. Goletz, PubMed Cancer ImmunosurveillanceRegulatory Cd4T CellsLate-stage Ovarian CancerImmunology	2001	1.1K
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. Maurie Markman, Robert Rothman, Thomas B. Hakes, Journal of Clinical Oncology Surgical OncologyOverall Response RatesCisplatin ProgramsMedicineCancer Management	1991	851
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses David Cameron, Michelle Casey, Michael F. Press, Breast Cancer Research and Treatment Breast OncologyOncologyMedicinePhase IiiCapecitabine Versus Capecitabine	2008	801
Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial Robert L. Coleman, Mark F. Brady, Thomas J. Herzog, The Lancet Oncology Paclitaxel–carboplatin ChemotherapySecondary CytoreductionMedicineMetronomic TherapyPharmacology	2017	585
Clinical and Pathological Features of Ovarian Cancer in Women with Germ-Line Mutations of<i>BRCA1</i> Stephen C. Rubin, Ivor Benjamin, Kian Behbakht, New England Journal of Medicine	1996	431
Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study William E. Winter, G. Larry Maxwell, Chunqiao Tian, Journal of Clinical Oncology	2007	403
Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma Peter G. Rose, Stacy Nerenstone, Mark F. Brady, New England Journal of Medicine	2004	399
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer John K. Chan, Mark F. Brady, Richard T. Penson, New England Journal of Medicine	2016	355
Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. Maurie Markman, Eric K. Rowinsky, Thomas B. Hakes, Journal of Clinical Oncology	1992	313

Page 1